News | January 05, 2023
Biocytogen and Hansoh Pharma announce an antibody license agreement
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Acquisitions have the potential to add at least $1 billion in sales by 2028
The Government of India is supporting the states in active case detection, surveillance, treatment, supply of diagnostic kits, medicines, sprays etc.
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
To create leading company developing medicines targeting metalloenzymes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
